Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Clobenpropit dihydrobromide is a potent antagonist and inverse agonist of histamine H3R (histamine H3LR,pEC50 of 8.07)
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 38.00 | |
5 mg | In stock | $ 89.00 | |
10 mg | In stock | $ 155.00 | |
25 mg | In stock | $ 347.00 | |
50 mg | In stock | $ 587.00 | |
100 mg | In stock | $ 839.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 108.00 |
Description | Clobenpropit dihydrobromide is a potent antagonist and inverse agonist of histamine H3R (histamine H3LR,pEC50 of 8.07) |
Targets&IC50 | H2 receptor:5.6 (pKi), Human H3LR:9.44 (pKi), H4 receptor:13 nM (Ki), Rat H3LR:9.75 (pKi) |
In vitro | Clobenpropit inhibited cell migration and increased apoptosis of pancreatic cancer cells in combination with gemcitabine.?Clobenpropit up-regulated E-cadherin, but down-regulated vimentin and matrix metalloproteinase 9 in real-time polymerase chain reaction[1]. |
In vivo | Clobenpropit inhibited tumor growth (gemcitabine 294 46 mg vs combination 154 54 mg, P = 0.02) and enhanced apoptosis in combination with gemcitabine (control 2.5%, gemcitabine 25.8%, clobenpropit 9.7% and combination 40.9%, P = 0.001) by up-regulation of E-cadherin and down-regulation of Zeb1 in Panc-1 xenograft mouse. |
Cell Research | Pancreatic cancer cells (Panc-1, MiaPaCa-2 and AsPC-1).Concentration: 50 Μm |
Molecular Weight | 470.7 |
Formula | C14H19Br2ClN4S |
CAS No. | 145231-35-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.71 mg/mL (10 mM), Sonification is recommended
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Clobenpropit dihydrobromide 145231-35-2 Apoptosis GPCR/G Protein Immunology/Inflammation Neuroscience Histamine Receptor inhibit Clobenpropit histamine H3R antagonist inverse Inhibitor pancreatic agonist cancer H3LR Clobenpropit Dihydrobromide inhibitor